Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) EBIAT (2016 - 2025)

Zevra Therapeutics' EBIAT history spans 11 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, EBIAT rose 134.04% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $83.2 million, up 178.88%, while the annual FY2025 figure was $83.2 million, 178.88% up from the prior year.
  • EBIAT reached $12.2 million in Q4 2025 per ZVRA's latest filing, up from -$544000.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $74.7 million in Q2 2025 to a low of -$35.7 million in Q4 2024.
  • Average EBIAT over 5 years is -$5.9 million, with a median of -$6.7 million recorded in 2022.
  • Peak YoY movement for EBIAT: surged 622.12% in 2021, then tumbled 1213.13% in 2022.
  • A 5-year view of EBIAT shows it stood at -$2.7 million in 2021, then crashed by 1213.13% to -$35.5 million in 2022, then soared by 80.84% to -$6.8 million in 2023, then plummeted by 425.57% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EBIAT are $12.2 million (Q4 2025), -$544000.0 (Q3 2025), and $74.7 million (Q2 2025).